Syros Pharmaceuticals Inc (NASDAQ:SYRS) – Investment analysts at Wedbush cut their FY2017 earnings per share estimates for shares of Syros Pharmaceuticals in a report issued on Tuesday. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($2.10) per share for the year, down from their prior estimate of ($1.99). Wedbush also issued estimates for Syros Pharmaceuticals’ Q4 2017 earnings at ($0.56) EPS, Q1 2018 earnings at ($0.46) EPS, Q2 2018 earnings at ($0.53) EPS, Q3 2018 earnings at ($0.60) EPS, Q4 2018 earnings at ($0.65) EPS, FY2018 earnings at ($2.24) EPS, FY2019 earnings at ($2.26) EPS, FY2020 earnings at ($1.99) EPS and FY2021 earnings at ($1.82) EPS.
Several other research analysts also recently weighed in on SYRS. Cann reiterated a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a report on Monday, August 21st. ValuEngine downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. JMP Securities upgraded Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price target for the company in a report on Thursday, September 28th. Zacks Investment Research downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, Roth Capital initiated coverage on Syros Pharmaceuticals in a report on Monday, October 23rd. They issued a “neutral” rating and a $15.00 price target for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $26.14.
Syros Pharmaceuticals (SYRS) opened at $9.08 on Thursday. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.53).
Several hedge funds and other institutional investors have recently made changes to their positions in SYRS. FMR LLC grew its stake in shares of Syros Pharmaceuticals by 11.9% during the 2nd quarter. FMR LLC now owns 3,926,998 shares of the company’s stock valued at $63,185,000 after buying an additional 418,061 shares during the period. Vanguard Group Inc. grew its stake in shares of Syros Pharmaceuticals by 189.6% during the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after buying an additional 250,507 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in shares of Syros Pharmaceuticals during the 3rd quarter valued at $1,766,000. State Street Corp grew its stake in shares of Syros Pharmaceuticals by 176.7% during the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after buying an additional 108,250 shares during the period. Finally, AWM Investment Company Inc. grew its stake in shares of Syros Pharmaceuticals by 155.8% during the 2nd quarter. AWM Investment Company Inc. now owns 121,624 shares of the company’s stock valued at $1,957,000 after buying an additional 74,074 shares during the period. 58.02% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Wedbush Equities Analysts Lower Earnings Estimates for Syros Pharmaceuticals Inc (SYRS)” was originally published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.truebluetribune.com/2017/12/14/wedbush-equities-analysts-lower-earnings-estimates-for-syros-pharmaceuticals-inc-syrs.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.